Donors must meet certain criteria, including COVID illness and recovery within the last several months, so that antibodies will be relevant for newer variants of the virus

AION Labs, a consortium formed by Pfizer, Merck, AstraZeneca, Teva and others, sets up company to build a computational platform to design live-saving antibodies from scratch

Computer-designed antibodies can be programmed to do much more when designed from scratch than when based on animal/human antibodies, says inventor

Diaspora reporter Judah Ari Gross delves into a shocking story out of Poland; health reporter Nathan Jeffay brings us the latest in COVID research and a cancer detection blood test

Cancer patients currently need to visit a hospital for treatment; Israeli-Portuguese research could change this, scientists say, although potential drug years away

Team says such tests could be used as a screening tool for the allocation of the first batches of updated vaccines, once these arrive

Researchers say ointment could become standard medication, but long path ahead; chemical ‘jams’ communication between bacteria at injury site, making healing easier

Did the travel ban help? Why aren’t vaccines working the same as with previous variants? Why don’t antibody counts tell us if we’re protected? Immunologist Dr. Yariv Wine answers

Virologist predicts shortage of GlaxoSmithKline's drug, the only one that remains effective, after Regeneron, Eli Lilly say their therapies appear less useful against new strain

AstraZeneca's Evusheld okayed for those 12 and older who didn't respond adequately to vaccines or who have history of severe allergic reactions to shots